hello, exactly 6 years ago I bought AMBS ..... never recurrence was better ....

- "The value of the total consideration ultimately expected to be received by Amarantus from Coeptis upon this sale is greater than all of the Company's outstanding liabilities combined."
- look who IDEA clients are; Boehringer Ingelheim, Bristol, J&J, Novartis, Pfizer, Roche, and many more
- IDEA has 6k Followers on LinkedIn, 10x AMBS
- manf is still ours
- everything seems to move in the right direction


happy for the new investors that will arrive .... I emphasize investors .... unfortunately will come many "hit and run" .... without having understood what they had in the portfolio .... at miserable 100 million market cap we would be 20x the current evaluation ....
lucky who buys these figures
greetings from Italy
Paolo